ATE173630T1 - Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren - Google Patents

Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren

Info

Publication number
ATE173630T1
ATE173630T1 AT94905355T AT94905355T ATE173630T1 AT E173630 T1 ATE173630 T1 AT E173630T1 AT 94905355 T AT94905355 T AT 94905355T AT 94905355 T AT94905355 T AT 94905355T AT E173630 T1 ATE173630 T1 AT E173630T1
Authority
AT
Austria
Prior art keywords
interferon
treatment
inflammatory bowel
bowel disease
gamma inhibitors
Prior art date
Application number
AT94905355T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Rebecca H R Ward
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE173630T1 publication Critical patent/ATE173630T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
AT94905355T 1992-12-29 1993-12-09 Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren ATE173630T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99783592A 1992-12-29 1992-12-29

Publications (1)

Publication Number Publication Date
ATE173630T1 true ATE173630T1 (de) 1998-12-15

Family

ID=25544454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94905355T ATE173630T1 (de) 1992-12-29 1993-12-09 Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren

Country Status (12)

Country Link
US (5) US6558661B1 (de)
EP (1) EP0695189B1 (de)
JP (1) JP3887011B2 (de)
AT (1) ATE173630T1 (de)
AU (1) AU678429B2 (de)
CA (1) CA2148907C (de)
DE (1) DE69322289T2 (de)
DK (1) DK0695189T3 (de)
ES (1) ES2126094T3 (de)
IL (2) IL108007A (de)
WO (1) WO1994014467A1 (de)
ZA (1) ZA939577B (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0563487A1 (de) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
DK0695189T3 (da) * 1992-12-29 1999-08-09 Genentech Inc Behandling af inflammatorisk tarmsygdom med IFN-gammainhibitorer
US20020025316A1 (en) 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
AU2452797A (en) * 1996-04-10 1997-10-29 Board Of Trustees Of The University Of Illinois, The Interferon-gamma anti-inflammatory methods, compounds, and pharmaceutical compositions
US6410824B1 (en) 1998-12-09 2002-06-25 Protein Design Labs, Inc. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US6348316B1 (en) 2000-04-12 2002-02-19 Cedars-Sinai Medical Center Genetic testing for determining the risk of pouchitis development
GB0009503D0 (en) * 2000-04-17 2000-06-07 Univ Liverpool Screening method for compounds
AU2001257445B2 (en) 2000-04-28 2006-11-02 Planet Biotechnology, Inc. Immunoadhesin for the prevention of rhinovirus infection
AU2003214023A1 (en) * 2002-03-12 2003-09-22 Novo Nordisk A/S Dimeric tf antagonist comprising two factor vii polypeptides
US7060685B2 (en) 2002-05-16 2006-06-13 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
EP1506002A4 (de) * 2002-05-17 2006-06-07 Protein Design Labs Behandlung von morbus crohn oder psoriasis mit anti-inteferon gamma antikörpern
CA2490703A1 (en) * 2002-07-03 2004-01-15 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
EP1542708A4 (de) * 2002-08-23 2006-04-19 Zymogenetics Inc Verfahren zur behandlung von entz ndlicher darmerkrankung
WO2004034988A2 (en) * 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
US7282202B2 (en) * 2003-02-24 2007-10-16 Morinaga Milk Industry Co., Ltd. Interleukin-6 suppressive agent
EP1631312B1 (de) * 2003-04-23 2008-09-10 Medarex, Inc. Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
GB0323793D0 (en) * 2003-10-10 2003-11-12 Imp College Innovations Ltd Methods
JP2007524658A (ja) * 2003-11-19 2007-08-30 グリコミメティクス， インコーポレイテッド Ｅ−およびｐ−セレクチンの両方のための糖模倣物アンタゴニスト
WO2005051920A2 (en) * 2003-11-19 2005-06-09 Glycomimetics, Inc. Specific antagonist for both e- and p-selectins
US20050260155A1 (en) * 2004-05-18 2005-11-24 Gopala Kovvali Compositions and methods for treatment of ulcerative colitis
DK2662390T3 (da) 2004-06-21 2017-11-06 Squibb & Sons Llc Interferon alpha receptor 1-antistoffer og anvendelse heraf
US20060040258A1 (en) * 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
CN101151277B (zh) 2005-01-27 2013-11-13 诺维莫尼公司 抗干扰素γ抗体及其使用方法
US20060205090A1 (en) * 2005-03-14 2006-09-14 Newton Michael W Water-soluble conjugates for electrochemical detection
WO2006127906A1 (en) * 2005-05-25 2006-11-30 Glycomimetics, Inc. Heterobifunctional compounds for selectin inhibition
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
CA2618638C (en) * 2005-08-09 2014-03-11 Glycomimetics, Inc. Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas
JP5209476B2 (ja) 2005-09-02 2013-06-12 グリコミメティクス， インコーポレイテッド ヘテロ二官能性全セレクチン阻害剤
US20090176717A1 (en) * 2006-06-01 2009-07-09 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
JP5298020B2 (ja) 2006-10-12 2013-09-25 グリコミメティクス， インコーポレイテッド ヘキソースおよびｎ−アセチルヘキソサミンの糖模倣体置換
NZ598863A (en) * 2007-02-09 2013-11-29 Glycomimetics Inc Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
US8039442B2 (en) * 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
WO2009152245A1 (en) * 2008-06-13 2009-12-17 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
MX2011000039A (es) * 2008-07-02 2011-05-31 Emergent Product Dev Seattle Proteinas antagonistas del factor-beta de crecimiento transformante (tgf-beta), que se unen a multiples objetivos.
EA201170028A1 (ru) * 2008-07-02 2011-12-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2010126888A1 (en) 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US9848760B2 (en) * 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
KR20140097336A (ko) 2011-11-23 2014-08-06 암젠 인크 인터페론 감마에 대한 항체를 이용한 치료 방법
ES2655443T7 (es) 2011-12-22 2021-03-22 Glycomimetics Inc Compuestos antagonistas de E-selectina
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
CA2891514C (en) 2012-12-07 2020-08-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
EP2970483A2 (de) 2013-03-15 2016-01-20 Amgen Inc. Verfahren und zusammensetzungen im zusammenhang mit anti-ccr7-antigen-bindenden proteinen
CN105246501B (zh) 2013-03-27 2021-01-12 雪松-西奈医学中心 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
CN107108679B (zh) 2014-12-03 2020-10-23 糖模拟物有限公司 E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂
CA2978616A1 (en) * 2015-03-16 2016-09-22 Cedars-Sinai Medical Center Methods of treating inflammatory bowel disease with ifn-gamma therapy
EA037532B1 (ru) 2015-05-07 2021-04-08 Новиммун Са Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
CA3009836A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
EP3430172A4 (de) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center Verfahren zur diagnose einer entzündlichen darmerkrankung durch rnaset2
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
JP7069136B2 (ja) 2016-10-07 2022-05-17 グリコミメティクス， インコーポレイテッド 極めて強力な多量体ｅ－セレクチンアンタゴニスト
US10266745B2 (en) * 2017-02-03 2019-04-23 Saudi Arabian Oil Company Anti-bit balling drilling fluids, and methods of making and use thereof
JP7272956B2 (ja) 2017-03-15 2023-05-12 グリコミメティクス， インコーポレイテッド Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
AU2019230013A1 (en) 2018-03-05 2020-09-10 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
GB8519848D0 (en) 1985-08-07 1985-09-11 Schweiz Rotes Kreuz Treatment of chronic inflammatory disease
IL78444A (en) 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
EP0269408A3 (de) 1986-11-26 1989-08-30 Genentech, Inc. TGF-Beta für die Behandlung von entzündlichen Erkrankungen
IL88378A (en) 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0393502B1 (de) * 1989-04-19 1995-12-27 F. Hoffmann-La Roche Ag Auflösbare Interferon-gamma-Rezeptoren sowie Verfahren zu deren Herstellung
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL91562A0 (en) 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
HUT62936A (en) 1990-04-24 1993-06-28 Schering Corp Process for producing soluble reduced gamma interferon receptors
DE69115917T2 (de) 1990-09-27 1996-05-23 Schering Corp Humane gammainterferonantagonisten
DK0695189T3 (da) * 1992-12-29 1999-08-09 Genentech Inc Behandling af inflammatorisk tarmsygdom med IFN-gammainhibitorer
CA2114168A1 (en) 1993-03-05 1994-09-06 Zlatko Dembic Chimeric human interferon-gamma-receptor/immunoglobulin polypeptides
JPH0746628A (ja) * 1993-06-29 1995-02-14 Toshiba Corp 画像信号符号化装置及び画像信号復号化装置
DE69942671D1 (de) 1998-12-01 2010-09-23 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
EP1506002A4 (de) 2002-05-17 2006-06-07 Protein Design Labs Behandlung von morbus crohn oder psoriasis mit anti-inteferon gamma antikörpern
US20050019323A1 (en) 2002-05-22 2005-01-27 Protein Design Labs, Inc. Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies

Also Published As

Publication number Publication date
ES2126094T3 (es) 1999-03-16
CA2148907A1 (en) 1994-07-07
IL108007A0 (en) 1994-04-12
AU5898894A (en) 1994-07-19
EP0695189A1 (de) 1996-02-07
AU678429B2 (en) 1997-05-29
US20070020268A1 (en) 2007-01-25
US20070104712A1 (en) 2007-05-10
US20030012787A1 (en) 2003-01-16
IL108007A (en) 2005-08-31
US6558661B1 (en) 2003-05-06
JPH08504817A (ja) 1996-05-28
EP0695189B1 (de) 1998-11-25
JP3887011B2 (ja) 2007-02-28
DE69322289D1 (de) 1999-01-07
US20030012790A1 (en) 2003-01-16
DK0695189T3 (da) 1999-08-09
US7300656B2 (en) 2007-11-27
DE69322289T2 (de) 1999-05-20
ZA939577B (en) 1995-06-21
CA2148907C (en) 2008-07-08
IL124478A0 (en) 1998-12-06
WO1994014467A1 (en) 1994-07-07
US7449176B2 (en) 2008-11-11

Similar Documents

Publication Publication Date Title
ATE173630T1 (de) Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
MX9602818A (es) Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69622894D1 (de) Substituierte Sulfonylphenylheterocyclen als Cyclooxygenase-2 und 5- Lipoxygenase Inhibitoren
DK0705100T3 (da) Terapeutiske substituerede guanidiner
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
BG101841A (en) Cellular adhesion inhibitors
TR199902545T2 (xx) Kalp damar hastal�klar�n�n �nlenmesinde siklooksijenaz-2 inhibit�rlerini kullanma y�ntemi
LV12209A (lv) Ar fenilgrupu aizvietoti heterocikli ka ciklooksigenazes-2 inhibitori
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
NO996578L (no) Urokinase-inhibitorer
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
ATE171935T1 (de) 2-amino-4-phenyl-4-oxo-buttersäure-derivate mit kynureninase und/oder kynurenin-3-hydroxylase inhibierender wirkung
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
TR199901703T2 (xx) Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
MXPA04002565A (es) Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ATE128871T1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
ATE218877T1 (de) Bowman-birk-inhibitorzusammensetzungen zur behandlung von entzündungskrankheiten
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification